How gut Microbiome composition affects immunotherapy responses in mouse models of cancer
Eduardo Pareja commented about two recent papers in Science and a commentary paper also in Science that pointed to the importance of gut microbiome composition in the immunotherapy of cancer. Both of them have been done in a melanoma model in mice. The immunoptherapy (check-point blockade) was done in PD-L1 in one case and in CTLA4 in the other.
The impact of that will be at least the immediate incorporation of metagenomics analysis in experimental studies and clinical trials for cancer immunotherapy.